Volume Alert - NVAX 4.96 Novavax Inc $NVAX Hit a high today of 5.08 Closing the day 10:30 at 4.96 +0.12 +2.48% With a day low of 4.93 and a total volume of 1,659,753.
NVAX Recent Posts: http://investorshangout.com/Novavax-Inc-NVAX-54932/
NVAX Novavax Inc Recent Headline News
Novavax RSV vaccine candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - 2 hrs 11 mins ago
NVAX: 5.02 (+0.18)
U.S. FDA Grants Fast Track Designation to Novavax' RSV F-Protein Nanoparticle Vaccine for Protection of Infants Via Maternal Immunization
GlobeNewswire - 2 hrs 32 mins ago
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax' RSV F-Protein nanoparticle vaccine candidate (RSV F vaccine) for protection of infants via maternal immunization.
NVAX: 5.02 (+0.18)
InsiderInsights.com Daily Round Up 11/18/14: NES, TTS, RCAP, GSAT
InsiderInsights - at Seeking Alpha - Wed Nov 19, 3:29AM CST
CLUB: 6.27 (+0.20), MLM: 128.93 (+0.74), NES: 8.64 (+0.66), VOYA: 41.42 (-0.02), THG: 70.38 (+0.48), RXN: 27.00 (+0.09), GSAT: 2.59 (-0.08), LKFN: 40.30 (+0.01), PCLN: 1,159.29 (+2.64), TTS: 9.23 (+0.68), RCAP: 11.60 (-0.30), SPW: 92.79 (+0.48), NVAX: 5.02 (+0.18), WRLD: 77.00 (-1.37), TRUE: 17.90 (+0.32), BLMN: 22.07 (+0.25), BRX: 23.49 (-0.15), CMCSA: 54.37 (-0.01), SCHW: 28.37 (-0.15)
Today's Dead Cat Bounce Stock: Novavax (NVAX)
at The Street - Tue Nov 18, 9:26AM CST
Trade-Ideas LLC identified Novavax (NVAX) as a "dead cat bounce" (down big yesterday but up big today) candidate
NVAX: 5.02 (+0.18)
Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Novavax Is Up 2.9% (NVAX)
Comtex SmarTrend(R) - Mon Nov 17, 3:56PM CST
When Novavax (NASDAQ:NVAX) reported earnings 12 days ago on November 5th, 2014, analysts, on average, expected the company to report a loss of $0.07 on sales of $9.4 million. The company actually reported a loss of $0.08 per share on sales of $8.2 million, missing EPS estimates by $0.01 and missing revenue estimates by $1.2 million. Since the company's report, shares of Novavax have risen from $5.13 to $5.28, representing a gain of 2.9% in the past 12 days.
NVAX: 5.02 (+0.18)
Novavax Initiates Phase 2 Clinical Trial of Quadrivalent Seasonal Influenza VLP
Thomson Reuters ONE - Mon Nov 17, 3:07PM CST
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
NVAX: 5.02 (+0.18)
Biotech Equities Technical Coverage - Orexigen Therapeutics, Novavax, Sunesis Pharma, Celldex Therapeutics, and Navidea Biopharma
PR Newswire - Mon Nov 17, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Orexigen Therapeutics Inc. (NASDAQ: OREX), Novavax Inc. (NASDAQ: NVAX), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 14, 2014, the NASDAQ Composite ended at 4,688.54, up 0.18%, the Dow Jones Industrial Average edged 0.10% lower, to finish the day at 17,634.74, and the S&P 500 closed at 2,039.82, up 0.02%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 777.26, down 0.83%, while the index has advanced 9.80% in the last one month. Register for your complimentary reports on these five stocks at:
OREX: 5.68 (unch), NAVB: 1.20 (-0.02), NVAX: 5.02 (+0.18), CLDX: 20.85 (+2.12), SNSS: 2.03 (-0.10)
Novavax to Present at the Jefferies Global Healthcare Conference
Thomson Reuters ONE - Thu Nov 13, 8:36AM CST
GAITHERSBURG, Md., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that Stanley C. Erck, President and CEO, will present at the Jefferies Global Healthcare Conference to be held on Thursday, November 20, 2014 at 9:20 a.m. U.S. EST (2:20 p.m. GMT) at the Waldorf Hilton Hotel in London, UK.
NVAX: 5.02 (+0.18)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 4.27 (-0.01), AGEN: 2.92 (-0.01), NVAX: 5.02 (+0.18), ALXN: 192.76 (+0.80), PPHM: 1.41 (+0.03), THLD: 3.07 (+0.13), GSK: 46.49 (+0.24), OMER: 21.06 (+0.09)
Rabies Therapeutic Market Pipeline Overview, Assessment, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 8:30PM CST
The report "Rabies - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/rabies-pipel...eport.html .
NVAX: 5.02 (+0.18), KMDA: 3.34 (-0.05), VBIV: 2.30 (-0.06), NNVC: 3.16 (+0.08), SVA: 5.05 (+0.04)
Shares of NVAX Up 14.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 11, 9:20AM CST
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 20th, 2014 at $4.54. In approximately 6 months, Novavax has returned 14.44% as of today's recent price of $5.19.
NVAX: 5.02 (+0.18)
Novavax Initiates Phase 1 Clinical Trial of RSV F Vaccine in Pediatric Subjects
GlobeNewswire - Mon Nov 10, 7:44AM CST
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy children, the first study of this vaccine candidate to be conducted in a pediatric population.
NVAX: 5.02 (+0.18)
Why Novavax, Inc. Stock Skyrocketed 34% in October
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 07, 10:05AM CST
NVAX data by YCharts What: Shares of Novavax , a clinical-stage biopharmaceutical company focused on developing vaccines and adjuvants to fight various types of infectious diseases, skyrocketed 34% in October, based on data from S&P...
NVAX: 5.02 (+0.18)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.27 (-0.01), PCYC: 138.34 (-0.26), CLDX: 20.87 (+2.14), INCY: 71.90 (+0.60), BIND: 7.75 (-0.65), CELG: 107.62 (+0.64), OMER: 21.06 (+0.09), VSTM: 8.80 (-0.01), GILD: 102.01 (-0.33), OGXI: 2.06 (-0.04), ANTH: 1.80 (-0.05), NVAX: 5.02 (+0.18)
Novavax and Collaborators Make Multiple Presentations at the 9th International Respiratory Syncytial Virus Symposium in South Africa, November 9-13, 2014
Thomson Reuters ONE - Thu Nov 06, 4:36PM CST
GAITHERSBURG, Md., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that representatives of Novavax, along with a number of its research collaborators, will be making multiple oral presentations and poster presentations related to Novavax' RSV F-protein nanoparticle vaccine candidate (RSV F Vaccine) at the 9th International Respiratory Syncytial Virus Symposium to be held November 9 - 13, 2014 in Stellenbosch, South Africa.
NVAX: 5.02 (+0.18)
NVAX Recent Posts: http://investorshangout.com/Novavax-Inc-NVAX-54932/
NVAX Novavax Inc Recent Headline News
Novavax RSV vaccine candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - 2 hrs 11 mins ago
NVAX: 5.02 (+0.18)
U.S. FDA Grants Fast Track Designation to Novavax' RSV F-Protein Nanoparticle Vaccine for Protection of Infants Via Maternal Immunization
GlobeNewswire - 2 hrs 32 mins ago
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax' RSV F-Protein nanoparticle vaccine candidate (RSV F vaccine) for protection of infants via maternal immunization.
NVAX: 5.02 (+0.18)
InsiderInsights.com Daily Round Up 11/18/14: NES, TTS, RCAP, GSAT
InsiderInsights - at Seeking Alpha - Wed Nov 19, 3:29AM CST
CLUB: 6.27 (+0.20), MLM: 128.93 (+0.74), NES: 8.64 (+0.66), VOYA: 41.42 (-0.02), THG: 70.38 (+0.48), RXN: 27.00 (+0.09), GSAT: 2.59 (-0.08), LKFN: 40.30 (+0.01), PCLN: 1,159.29 (+2.64), TTS: 9.23 (+0.68), RCAP: 11.60 (-0.30), SPW: 92.79 (+0.48), NVAX: 5.02 (+0.18), WRLD: 77.00 (-1.37), TRUE: 17.90 (+0.32), BLMN: 22.07 (+0.25), BRX: 23.49 (-0.15), CMCSA: 54.37 (-0.01), SCHW: 28.37 (-0.15)
Today's Dead Cat Bounce Stock: Novavax (NVAX)
at The Street - Tue Nov 18, 9:26AM CST
Trade-Ideas LLC identified Novavax (NVAX) as a "dead cat bounce" (down big yesterday but up big today) candidate
NVAX: 5.02 (+0.18)
Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Novavax Is Up 2.9% (NVAX)
Comtex SmarTrend(R) - Mon Nov 17, 3:56PM CST
When Novavax (NASDAQ:NVAX) reported earnings 12 days ago on November 5th, 2014, analysts, on average, expected the company to report a loss of $0.07 on sales of $9.4 million. The company actually reported a loss of $0.08 per share on sales of $8.2 million, missing EPS estimates by $0.01 and missing revenue estimates by $1.2 million. Since the company's report, shares of Novavax have risen from $5.13 to $5.28, representing a gain of 2.9% in the past 12 days.
NVAX: 5.02 (+0.18)
Novavax Initiates Phase 2 Clinical Trial of Quadrivalent Seasonal Influenza VLP
Thomson Reuters ONE - Mon Nov 17, 3:07PM CST
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
NVAX: 5.02 (+0.18)
Biotech Equities Technical Coverage - Orexigen Therapeutics, Novavax, Sunesis Pharma, Celldex Therapeutics, and Navidea Biopharma
PR Newswire - Mon Nov 17, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Orexigen Therapeutics Inc. (NASDAQ: OREX), Novavax Inc. (NASDAQ: NVAX), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 14, 2014, the NASDAQ Composite ended at 4,688.54, up 0.18%, the Dow Jones Industrial Average edged 0.10% lower, to finish the day at 17,634.74, and the S&P 500 closed at 2,039.82, up 0.02%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 777.26, down 0.83%, while the index has advanced 9.80% in the last one month. Register for your complimentary reports on these five stocks at:
OREX: 5.68 (unch), NAVB: 1.20 (-0.02), NVAX: 5.02 (+0.18), CLDX: 20.85 (+2.12), SNSS: 2.03 (-0.10)
Novavax to Present at the Jefferies Global Healthcare Conference
Thomson Reuters ONE - Thu Nov 13, 8:36AM CST
GAITHERSBURG, Md., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that Stanley C. Erck, President and CEO, will present at the Jefferies Global Healthcare Conference to be held on Thursday, November 20, 2014 at 9:20 a.m. U.S. EST (2:20 p.m. GMT) at the Waldorf Hilton Hotel in London, UK.
NVAX: 5.02 (+0.18)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 4.27 (-0.01), AGEN: 2.92 (-0.01), NVAX: 5.02 (+0.18), ALXN: 192.76 (+0.80), PPHM: 1.41 (+0.03), THLD: 3.07 (+0.13), GSK: 46.49 (+0.24), OMER: 21.06 (+0.09)
Rabies Therapeutic Market Pipeline Overview, Assessment, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 8:30PM CST
The report "Rabies - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/rabies-pipel...eport.html .
NVAX: 5.02 (+0.18), KMDA: 3.34 (-0.05), VBIV: 2.30 (-0.06), NNVC: 3.16 (+0.08), SVA: 5.05 (+0.04)
Shares of NVAX Up 14.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 11, 9:20AM CST
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 20th, 2014 at $4.54. In approximately 6 months, Novavax has returned 14.44% as of today's recent price of $5.19.
NVAX: 5.02 (+0.18)
Novavax Initiates Phase 1 Clinical Trial of RSV F Vaccine in Pediatric Subjects
GlobeNewswire - Mon Nov 10, 7:44AM CST
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy children, the first study of this vaccine candidate to be conducted in a pediatric population.
NVAX: 5.02 (+0.18)
Why Novavax, Inc. Stock Skyrocketed 34% in October
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 07, 10:05AM CST
NVAX data by YCharts What: Shares of Novavax , a clinical-stage biopharmaceutical company focused on developing vaccines and adjuvants to fight various types of infectious diseases, skyrocketed 34% in October, based on data from S&P...
NVAX: 5.02 (+0.18)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.27 (-0.01), PCYC: 138.34 (-0.26), CLDX: 20.87 (+2.14), INCY: 71.90 (+0.60), BIND: 7.75 (-0.65), CELG: 107.62 (+0.64), OMER: 21.06 (+0.09), VSTM: 8.80 (-0.01), GILD: 102.01 (-0.33), OGXI: 2.06 (-0.04), ANTH: 1.80 (-0.05), NVAX: 5.02 (+0.18)
Novavax and Collaborators Make Multiple Presentations at the 9th International Respiratory Syncytial Virus Symposium in South Africa, November 9-13, 2014
Thomson Reuters ONE - Thu Nov 06, 4:36PM CST
GAITHERSBURG, Md., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that representatives of Novavax, along with a number of its research collaborators, will be making multiple oral presentations and poster presentations related to Novavax' RSV F-protein nanoparticle vaccine candidate (RSV F Vaccine) at the 9th International Respiratory Syncytial Virus Symposium to be held November 9 - 13, 2014 in Stellenbosch, South Africa.
NVAX: 5.02 (+0.18)
